Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

Dagnew Alemnew F.; Ilhan Osman; Lee Won-Sik; Woszczyk Dariusz; Kwak Jae-Yong; Bowcock Stella; Sohn Sang Kyun; Rodriguez Macias Gabriela; Chiou Tzeon-Jye; Quiel Dimas; Aoun Mickael; Navarro Matilla Maria Belen; de la Serna Javier; Milliken Samuel; Murphy John; McNeil Shelly A.; Salaun Bruno; Di Paolo Emmanuel; Campora Laura; Lopez-Fauqued Marta; El Idrissi Mohamed; Schuind Anne; Heineman Thomas C.; Van den Steen Peter; Oostvogels Lidia

首页> 外文期刊>The Lancet infectious diseases >Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

【24h】

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

机译：呼吸性重组带状疱疹的免疫原性和安全性具有血液恶性肿瘤的成人中：A相，随机，临床试验和HOC疗效分析

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background The adjuvanted recombinant zoster vaccine (Shingrix) can prevent herpes zoster in older adults and autologous haemopoietic stem cell transplant recipients. We evaluated the safety and immunogenicity of this vaccine in adults with haematological malignancies receiving immunosuppressive cancer treatments.

机译：背景技术佐剂重组枢毛疫苗（Shingrix）可以预防老年人的疱疹带状疱疹和自体血液能干细胞移植受者。我们评估了这种疫苗在具有接受免疫抑制癌症治疗的血液恶性恶性肿瘤的疫苗的安全性和免疫原性。

著录项

来源
《The Lancet infectious diseases》 |2019年第9期|共13页
作者
Dagnew Alemnew F.; Ilhan Osman; Lee Won-Sik; Woszczyk Dariusz; Kwak Jae-Yong; Bowcock Stella; Sohn Sang Kyun; Rodriguez Macias Gabriela; Chiou Tzeon-Jye; Quiel Dimas; Aoun Mickael; Navarro Matilla Maria Belen; de la Serna Javier; Milliken Samuel; Murphy John; McNeil Shelly A.; Salaun Bruno; Di Paolo Emmanuel; Campora Laura; Lopez-Fauqued Marta; El Idrissi Mohamed; Schuind Anne; Heineman Thomas C.; Van den Steen Peter; Oostvogels Lidia;
展开▼
作者单位

GSK Rockville MD 20850 USA;

Ankara Univ Fac Med Dept Hematol Ankara Turkey;

Inje Univ Busan Paik Hosp Dept Hematooncol Internal Med Busan South Korea;

Univ Opole Prov Hosp Dept Haematol Opole Poland;

Chonbuk Natl Univ Med Sch &

Hosp Dept Internal Med Jeonju South Korea;

Kings Coll Hosp London Dept Haematol Med London England;

Kyungpook Natl Univ Sch Med Dept Internal Med Daegu South Korea;

Gregorio Maranon Univ Hosp Dept Hematol Madrid Spain;

Taipei Vet Gen Hosp Dept Med Div Transfus Med Taipei Taiwan;

Complejo Hosp Metropolitano Dr Arnulfo Arias Madr Panama City Panama;

Inst Jules Bordet Dept Infect Dis Brussels Belgium;

Hosp Univ Puerta de Hierro Majadahonda Dept Hematol Madrid Spain;

Hosp Univ 12 Octubre Dept Hematol Madrid Spain;

St Vincents Hosp Kinghorn Canc Ctr Dept Haematol Darlinghurst NSW Australia;

NHS Lanarkshire Univ Hosp Monklands Dept Haematol Airdrie Scotland;

Dalhousie Univ IWK Hlth Ctr Canadian Ctr Vaccinol Halifax NS Canada;

GSK Rixensart Belgium;

GSK Rixensart Belgium;

GSK Wavre Belgium;

GSK Wavre Belgium;

GSK Rixensart Belgium;

GSK Rockville MD 20850 USA;

Halozyme Therapeut San Diego CA USA;

GSK Wavre Belgium;

CureVac Tubingen Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类传染病;
关键词

相似文献

外文文献
中文文献
专利

1. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised clinical trials and post-hoc efficacy analysis (vol 19, pg 988, 2019) [J] . Dagnew A. F., Ilhan A., Lee W-S The Lancet infectious diseases . 2020,第1期

机译：具有血液恶性肿瘤的成人中佐剂重组带状疫苗的免疫原性和安全性：第3期，随机临床试验和HOC后疗效分析（Vol 19，PG 988,2019）
2. Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial [J] . Czechoslovak Mathematical Journal . 2020,第2期

机译：在肾移植后慢性免疫抑制成人中佐剂重组带状疫苗的免疫原性和安全性：A相3，随机临床试验
3. Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials [J] . Oostvogels Lidia, Heineman Thomas C., Johnson Robert W., Human vaccines & immunotherapeutics. . 2019,第12期

机译：注册的医疗病症不会影响佐剂重组带状疱疹的疗效和安全性：两个平行随机试验的汇集后HOC分析
4. A double-blind, randomized phase II trial of thesafety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adults [C] . Shelly A. McNeil, Scott A. Halperin, Joanne M. Langley, Lancefield International Symposium on Streptococci and Streptococcal Diseases . 2006

机译：一种双盲，随机期II试验，对健康成人的26岁的26岁群体的疫苗疫苗
5. Engineering a live attenuated vaccine: Mutational analysis of varicella-zoster virus (VZV) glycoproteins,gI andgE, in recombinant VZV strains. [D] . Mallory, Suzanne. 1997

机译：设计减毒活疫苗：重组VZV株中水痘带状疱疹病毒（VZV）糖蛋白，gI和gE的突变分析。
6. 149. Immunogenicity Safety and Post-hoc Efficacy Assessment of the Adjuvanted Recombinant Zoster Vaccine in Adults with Hematologic Malignancies: A Phase 3 Randomized Clinical Trial [O] . Alemnew F Dagnew, Osman Ilhan, Won-Sik Lee, -1

机译：149.成人血液系统恶性肿瘤佐剂重组带状疱疹疫苗的免疫原性安全性和事后功效评估：3期随机临床试验
7. Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in Adults with Hematologic Malignancies: A Phase III, Randomized Clinical Trial [O] . Lidia Oostvogels 2017

机译：佐剂疱疹的免疫原性和安全性，血液学恶性肿瘤中的成人患者疫苗疫苗：III期，随机临床试验

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅